Correction: GILD has not formally announced the discontinuation of GS-4774 for HBV, although the program may well be dead due to the lack of efficacy in a phase-2 trial reported in 2015 (#msg-114047018).
GBIM (GILD's partner on GS-4774) was -21% today despite the non-announcement!
Market Data 
Markets 
AI
